Our Science

TransCode Therapeutics believes it has overcome one of the greatest challenges facing targeted therapy for cancer- the challenge of delivering a functional therapeutic to the tumor while sparing healthy tissue. Our solution involves a proprietary delivery platform, called TTX, which is specifically designed to transport therapeutic payloads to tumors and metastases. 

Our therapeutic delivery strategy employs nanoparticles extensively used in imaging that have been repurposed and optimized to efficiently deliver payloads to oncology targets.
 
Preclinical evidence TTX has overcome delivery challenges:

• Superior stability, amenable for lyophilization (most payloads) avoiding cold chain logistics extending shelf-life potential
• Superior efficiency due to endosomal/lysosomal escape via the proton sponge effect for cytosolic delivery
• Unique capability for detection through noninvasive imaging enabling theranostic applicationstheranostics
• High tunability of size & surface chemistry enablingadaptation for desired tissue target (e.g., TME) and enormous flexibility for target delivery
• Simplicity and cost-effective production
• Safety - biodegradability and low immunogenicity
• Ready adaptability for stabilizing various types of payloads (including labile ones)

Yoo B, et al. J Biomed Nanotechnol. 2014;10(6):1114-1122.; Yigit MV, et al. Pharm Res. 2012;29(5):1180-1188.; Weissleder R, et al. Radiology. 1991;181(1):245-249.

View or download additional information on the TTX delivery platform and how TransCode is decoding the major challenge of RNA delivery. 

Download

preview